The group's principal activities are to develop, manufacture and market medical products designed to assist or replace the pumping function of the failing heart. the group currently manufactures and sells the bvs, a temporary heart assist device. bvs is an advanced heart assist device for the temporary treatment of all patients with failing but potentially recoverable hearts. the group's primary products under development are the abiocor system and the penn state heart. it is also engaged in research and development relating to other devices to replace or support the pumping function of the heart. the group's trademarks include abiomed, bvs, abiocor and angioflex . disposable blood pump, related accessories and services accounted for 92% of fiscal 2002 revenues and funded research and development, 8%.